Akèy › Leksemi biphenotipik egi › Missouri › Kansas City

Etid klinik pou Leksemi biphenotipik egi nan Kansas City, MO

4 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan ak bò kote Kansas City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Ap rekriteFaz 2

Children's Mercy Hospitals and Clinics, Kansas City

365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Ap rekriteFaz 3

Children's Mercy Hospitals and Clinics, Kansas City

365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Ap rekriteFaz 1/2

Children's Mercy Hospitals and Clinics, Kansas City

Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Ap rekriteFaz 1

Children's Mercy Hospital of Kansas City, Kansas City

Laj 1 a 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06177067

Etid Leksemi biphenotipik egi nan lòt vil

Lòt etid nan Kansas City

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.